Samidorphan
Lybalvi (samidorphan) is a small molecule pharmaceutical. Samidorphan was first approved as Lybalvi on 2021-05-28. It is used to treat bipolar disorder and schizophrenia in the USA. It is known to target delta-type opioid receptor, kappa-type opioid receptor, and mu-type opioid receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| mental disorders | D001523 |
Trade Name
FDA
EMA
Combinations
Lybalvi
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| lybalvi | New Drug Application | 2024-01-31 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
OLANZAPINE / SAMIDORPHAN L-MALATE, LYBALVI, ALKERMES INC | |||
| 2026-05-28 | NCE | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Olanzapine / Samidorphan L-Malate, Lybalvi, Alkermes Inc | |||
| 11707466 | 2041-11-12 | DP | |
| 8778960 | 2032-02-13 | U-3136, U-3137 | |
| 9119848 | 2031-08-30 | DP | |
| 9126977 | 2031-08-23 | DP | U-3136, U-3137 |
| 9517235 | 2031-08-23 | U-3138, U-3139 | |
| 10300054 | 2031-08-23 | DP | U-3140, U-3141 |
| 10716785 | 2031-08-23 | U-3136, U-3137 | |
| 11185541 | 2031-08-23 | U-3140 | |
| 11241425 | 2031-08-23 | U-3137 | |
| 11351166 | 2031-08-23 | U-3140, U-3141 | |
| 11793805 | 2031-08-23 | U-3734 | |
| 7262298 | 2025-11-23 | DP | |
HCPCS
No data
Clinical
Clinical Trials
35 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | 1 | 2 | 9 | — | — | 12 |
| Depression | D003863 | — | F33.9 | 1 | 1 | 6 | — | — | 7 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 1 | 1 | 6 | — | — | 7 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 1 | 1 | 6 | — | — | 7 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 1 | — | 4 | — | — | 5 |
| Psychotic disorders | D011618 | — | F20.81 | — | — | 2 | — | — | 2 |
| Body weight | D001835 | EFO_0004338 | — | — | — | 1 | — | — | 1 |
| Weight gain | D015430 | HP_0004324 | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alcoholism | D000437 | EFO_0003829 | F10.1 | 1 | 2 | — | — | — | 3 |
| Alcohol drinking | D000428 | EFO_0004329 | — | — | 1 | — | — | — | 1 |
| Bulimia | D002032 | — | F50.2 | — | 1 | — | — | — | 1 |
| Feeding and eating disorders | D001068 | — | F50 | — | 1 | — | — | — | 1 |
| Binge-eating disorder | D056912 | — | F50.2 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 6 | — | — | — | — | 6 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
| Cocaine-related disorders | D019970 | — | F14 | 1 | — | — | — | — | 1 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | — | 1 |
| Insulin resistance | D007333 | HP_0000855 | — | 1 | — | — | — | — | 1 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Samidorphan |
| INN | samidorphan |
| Description | Samidorphan is a member of phenanthrenes. |
| Classification | Small molecule |
| Drug class | narcotic antagonists/agonists (morphinan derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)CCC(=O)C3 |
Identifiers
| PDB | — |
| CAS-ID | 852626-89-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL426084 |
| ChEBI ID | — |
| PubChem CID | 11667832 |
| DrugBank | DB12543 |
| UNII ID | 7W2581Z5L8 (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Lybalvi – Alkermes
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 299 documents
View more details
Safety
Black-box Warning
Black-box warning for: Lybalvi
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
830 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use